MEASURING PREFERENCES FOR SCHIZOPHRENIA OUTCOMES

确定精神分裂症治疗的有效性需要 反映精神分裂症相对重要性的综合衡量标准 多个结果域。对亲人缺乏了解 各个领域的重要性阻碍了对结果的有意义的聚合 测量和限制从治疗研究中得出的推论。本研究 旨在开发和应用各种方法来确定 采用偏好评估方法治疗精神分裂症的效果 用于一般健康状况研究。 两个研究阶段中的第一个阶段致力于方法开发。四 偏好评估方法(类别评级、时间权衡、配对 比较和直接重要性评分)在既往健康中成功使用 现状研究将在两个专家组中进行评价，一个专家组由以下人员组成 提供精神分裂症治疗的临床医生和一名 精神分裂症。 在第二阶段，两种偏好评估方法被发现是 在方法开发阶段最可行、最有效和最可靠的将是 在包含4个利益相关者组的随机析因设计中进行比较 直接和间接参与精神分裂症治疗(有 精神分裂症，提供精神分裂症治疗的临床医生，家庭 精神分裂症患者及一般公众人士)。 此方法和组比较将(1)确定哪些方法执行 在可行性、有效性、 可靠性和效率，(2)决定利益相关者群体 会员资格或其他人口统计特征会影响对 治疗结果，(3)确定最适合未来使用的方法 精神分裂症治疗结果的研究，(4)产生偏好 关键结果的权重，可追溯应用于现有的 研究结果以及在偏好评估的未来研究中 是不切实际的。研究结果也将为其他研究提供参考 严重的精神障碍和帮助解决普遍存在的争议 关于方法和利益相关者群体在健康方面差异的重要性 身份偏好评估。

Determining the effectiveness of schizophrenia treatments requires aggregate measures that reflect the relative importance of schizophrenia's multiple outcome domains. A lack of understanding of the relative importance of various domains prevents meaningful aggregation of outcome measures and limits inferences drawn from treatment research. This study is designed to develop and apply methods for determining the importance of schizophrenia treatment outcomes by adapting preference assessment methods used in general health status research. The first of two study phases is devoted to method development. Four preference assessment methods (category rating, time trade-off, paired comparison and direct importance rating) used successfully in prior health status research will be evaluated in two expert groups, one comprised of clinicians providing schizophrenia treatment and one of persons with schizophrenia. In the second phase, the two preference assessment methods found to be most feasible, valid and reliable in the method development phase will be compared in a randomized, factorial design including 4 stakeholder groups directly and indirectly involved in schizophrenia treatment (persons with schizophrenia, clinicians providing schizophrenia treatment, family members of persons with schizophrenia and members of the general public). This method and group comparison will (1) determine which methods perform comparably across stakeholder groups in terms of feasibility, validity, reliability and efficiency, (2) determine whether stakeholder group membership or other demographic characteristics affect preferences for treatment outcomes, (3) identify methods best suited for use in future studies of schizophrenia treatment outcome, (4) generate preference weights for key outcomes which can be applied retrospectively to existing research findings as well as in future studies where preference assessment is not practical. Study findings will also inform the study of other serious mental disorders and help to resolve prevailing controversies about the importance of method and stakeholder group differences in health status preference assessment.